Reason for request
Reassessment
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of LYNPARZA (olaparib), monotherapy, remains substantial in the MA indication.
|
Clinical Added Value
| minor |
In view of:
- the evidence of the superiority of olaparib monotherapy versus placebo, in a randomised double-blind study, in terms of investigator-assessed progression-free survival: HR=0.30 [95%CI: 0.23-0.41], with a median progression-free survival not reached in the olaparib group and of 13.8 months in the placebo group,
- the lack of evidence of superiority on overall survival, despite the new data submitted,
- the lack of formal conclusion that can be drawn from the quality-of-life findings,
- the safety profile of olaparib, with in particular the onset of myelodysplastic syndromes/acute myeloid leukaemia,
the Committee deems that LYNPARZA (olaparib) monotherapy provides minor clinical added value (CAV IV) in the therapeutic strategy.
|
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
QFH6KwyPpNKBU7SE